No matter where a hereditary angioedema (HAE) attack occurs,

TREAT IT STOP IT FAST[1-3]

First and only oral on-demand treatment that helps your patients stop HAE attacks fast[2-4]

INDICATION

EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.[3]

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache.

NOW APPROVED

Please see additional Important Safety Information throughout.
Please see full Prescribing Information.

Actor portrayal

Ekterly®
(sebetralstat) tablets 300 mg

EKTERLY enables rapid treatment within minutes of recognizing an attack[1]

KONFIDENT was a multinational, randomized, double-blind, placebo-controlled, phase 3, crossover study of 136 patients from 17 countries[1,5]

Study participants were randomized to receive either placebo, EKTERLY 300 mg, or EKTERLY 600 mg to treat 3 attacks in a 3-way crossover design using 1 of 6 treatment sequences.

- Attacks in all locations were eligible for treatment[1]

EKTERLY halts HAE attacks fast for rapid symptom relief[1,3]

PRIMARY ENDPOINT

Median time to the beginning of symptom relief[1-3]

Defined as a rating of at least "a little better" for at least 2 consecutive timepoints on the Patient Global Impression of Change (PGI-C) scale within 12 hours of the first dose.

- Patients who reported at least "**a little better**" had **clinically meaningful improvement in attack symptoms**[6]

EKTERLY
1.8 hours*

PLACEBO
6.7 hours

One-dose symptom relief **96%** of attacks that reached the primary endpoint achieved symptom relief with only 1 dose[5]

*Based on prespecifying that attacks with incomplete data were censored at timepoint zero. Analysis included in label assigns these attacks a value of 12 hours, resulting in a median of 2.0 hours.[1,3]

IMPORTANT SAFETY INFORMATION

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Please see additional Important Safety Information throughout.
Please see full Prescribing Information.

Patients reported rapid time to symptom relief with EKTERLY[1,3]

Time to Beginning of Symptom Relief Within 12 Hours of Dosing[1-3,*]



- Some patients experienced symptom relief as early as 30 minutes after administration[2]
- Safety events with EKTERLY were similar to placebo[3]

Time to symptom relief was consistent across attack locations, severities, and patient demographics[1]

*This figure is based on the prespecified analysis in which attacks with incomplete data were censored at timepoint zero. In the FDA-approved labeling, these attacks were assigned a value of 12 hours, resulting in a different Kaplan-Meier curve. Using this method, 51% and 71% reached the endpoint by 2 hours and 4 hours, respectively.[1,3,7]

IMPORTANT SAFETY INFORMATION

Use in specific populations: Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B).

Please see additional Important Safety Information throughout.
Please see full Prescribing Information.

Ekterly®
(sebetralstat) tablets 300 mg

EKTERLY is the **first and only oral treatment** that lets patients treat at attack recognition[3,4]

Always ready to treat...

ANYTIME
No preparation or setup required[3]

ANYWHERE
Easily stored in a pocket, wallet, or bag[3]

- Taken with or without food[3]
- Smooth, film-coated tablets for easy swallowing[3,8]
- No refrigeration required[3]

INDICATION

EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache.

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Use in specific populations: Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B).

There are no available data on EKTERLY in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no data on the presence of sebetralstat or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

The safety and effectiveness of EKTERLY in pediatric patients aged under 12 years of age have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact KalVista Pharmaceuticals, Inc. at **1-855-258-4782** or FDA at **1-800-FDA-1088** or **www.fda.gov/medwatch**.

Please see full Prescribing Information.

References: 1. Riedl MA, Farkas H, Aygören-Pürsün E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. *N Engl J Med*. 2024;391(1):32-43. doi:10.1056/NEJMoa2314192 **2.** Data on File. KalVista Pharmaceuticals, Inc. 2024. **3.** EKTERLY. Package insert. KalVista Pharmaceuticals, Inc; 2025. **4.** KalVista Pharmaceuticals announces FDA approval of EKTERLY (sebetralstat), first and only oral on demand treatment for hereditary angioedema. Published July 2025. Accessed July 2025. **5.** Riedl MA, Farkas H, Aygören-Pürsün E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. *N Engl J Med*. 2024;391(1)(suppl 1):1-33. doi:10.1056/NEJMoa2314192 **6.** Cohn DM, Aygören-Pürsün E, Bernstein JA, et al. Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat. *Clin Transl Allergy*. 2023;13(9):e12288. doi:10.1002/clt2.12288 **7.** Data on File. KalVista Pharmaceuticals, Inc. 2025. **8.** Ershad AL, Rajabi-Siahboomi A, Missaghi S, Kirby D, Mohammed AR. Multi-analytical framework to assess the in vitro swallowability of solid oral dosage forms targeting patient acceptability and adherence. *Pharmaceutics*. 2021;13(3):411. doi:10.3390/pharmaceutics13030411

KalVista Pharmaceuticals

Ekterly®
(sebetralstat) tablets 300 mg